Radiopharmaceuticals Market Size, Share & Forecast 2026-2032
Published radiopharmaceutical market sizes spread 1.78x but their growth rates spread 3.35x. Disclosed FY2025 product revenue of $4.43bn shows why.
$8.1B
$12.5B
7.53%
Global
Executive Summary
Published estimates of the radiopharmaceuticals market put its base-year size between $5.8 billion (IMARC, 2024) and $10.3 billion (BCC Research, 2024) - a 1.78x spread, modest by the standards of this literature. The published growth rates, however, run from 4.9% to 16.4%, a 3.35x spread. That inversion is the finding. In most healthcare markets the analysts agree about growth and disagree about what to count. Here they disagree about growth, because the growth rate is doing the work of a scope decision.
The reason is visible in company filings. This market is the sum of two businesses pointing in opposite directions. In FY2025 Novartis reported Pluvicto net sales of $1,994 million, up 43% in USD, and Lutathera at $816 million, up 13%. Over the same year Lantheus reported Pylarify - the largest single disclosed diagnostic tracer - at $989.1 million, down 6.5%, with the fourth quarter down 9.7%, and guided FY2026 group revenue down to $1.40-1.45 billion from $1.54 billion. A 16.4% CAGR is a therapy-weighted forecast. A 4.9% CAGR is a generator-and-tracer-weighted forecast. Both can be internally consistent.
The disclosed revenue also tests the published sizes directly. Pluvicto, Lutathera, Pylarify and Telix's product revenue excluding third-party distribution sum to $4.43 billion for FY2025. Against IMARC's $5.8 billion that is 76% of the entire world market from four products, leaving roughly $1.37 billion for all Tc-99m generator supply, all FDG production, Xofigo, and the whole of Curium and Cardinal Health Nuclear. That is not credible, so the arithmetic rules out the low end of the published range. It is a plausibility test, not a market estimate: it sets a floor and eliminates candidates, and it says nothing about which of the surviving figures is right.
Key Highlights
Published base-year sizes spread 1.78x ($5.8B to $10.3B); published CAGRs spread 3.35x (4.9% to 16.4%) - the reverse of the usual pattern
The growth rate is a mix assumption: therapy grew (Pluvicto +43%, Lutathera +13% in FY2025 USD) while the largest disclosed diagnostic tracer shrank (Pylarify -6.5%)
Disclosed FY2025 product revenue across Pluvicto, Lutathera, Pylarify and Telix comes to $4.43 billion
That is 76% of the lowest published market size, which rules the low end out
Lantheus guided FY2026 revenue down to $1.40-1.45 billion from $1.54 billion, confirming the diagnostic contraction
102 lutetium-177 studies are registered on ClinicalTrials.gov, the pipeline behind the therapy-weighted forecasts
No vendor share is computable: Curium and Cardinal Health Nuclear are private, and Bayer does not disclose Xofigo separately
Market Overview
Market Context
A radiopharmaceutical is a drug whose active principle is a radionuclide, so the product's commercial logic is set by physics before economics. Lutetium-177 has a 6.6-day half-life and fluorine-18 under two hours, which means production, release testing, shipment and administration must happen inside a window measured in hours or days. The result is a market organised around proximity rather than scale: a radiopharmacy network, not a global supply chain. That is why the category splits so cleanly in the data. Commodity diagnostics - Tc-99m generators, FDG - behave like regional manufacturing with price erosion, and the one large disclosed example, Lantheus's Pylarify, declined 6.5% in FY2025. Targeted therapy behaves like oncology biologics, with per-patient revenue in the tens of thousands and growth constrained mainly by the number of licensed delivering sites and by label breadth, which is why Pluvicto grew 43% in a single year. The administering infrastructure is the real ceiling. Radioligand therapy requires a facility and an authorised user licensed under 10 CFR Part 35 or its Agreement State equivalent, so growth in therapy revenue depends on existing nuclear medicine departments taking on more patients rather than on new sites appearing. Published forecasts rarely state which of these two businesses they are modelling, and that silence is the single largest source of error in using them.
Published estimates put the radiopharmaceuticals market between $5.8 billion and $10.3 billion at a 2024 or 2025 base year, a 1.78x spread, while the published growth rates run from 4.9% to 16.4% - a 3.35x spread. That is the reverse of the usual pattern, and it is informative: the growth rate is where the scope decision hides, because this market is the sum of a fast-growing therapeutic business and a flat-to-declining diagnostic one. On the most recently based broad-scope series the market is $8.08 billion in 2026, reaching $12.49 billion by 2032 at 7.53%.
Market Stage
Growth
Adoption Level
Established in diagnostics, early in targeted therapy
Key Trends
Market Forecast & Data
Base Year (2026)
$8.1B
Forecast (2032)
$12.5B
CAGR (2026-2032)
7.53%
| Year | Market size ($ Billion) |
|---|---|
| 2026Base year | $8.08B |
| 2027 | $8.69B |
| 2028 | $9.34B |
| 2029 | $10.05B |
| 2030 | $10.80B |
| 2031 | $11.62B |
| 2032 | $12.49B |
The series shown here starts from Precedence Research's published 2025 estimate of $7.51 billion, advanced one year at Precedence's own published 7.53% CAGR to a 2026 base of $8.08 billion, and projected to $12.49 billion by 2032 on that same rate. The intermediate years are interpolation, not separately sourced observations. Precedence was chosen because it is the most recently based broad-scope estimate that the disclosed-revenue test does not rule out. Readers modelling therapy alone should expect a much higher rate and should anchor on disclosed product revenue rather than on any published market size: Pluvicto and Lutathera together were $2.81 billion in FY2025 and grew 33% combined in USD. Readers modelling generator and tracer supply should expect something closer to IMARC's 4.9%, and should note that the only large disclosed diagnostic product declined in 2025 and is guided lower for 2026. The 7.53% headline is therefore a blended rate whose accuracy depends entirely on a mix assumption that no published source discloses. Treat it as the midpoint of a genuinely unresolved question rather than as a measurement, and reconcile any forecast you are shown against the roughly $4.43 billion of revenue that companies actually disclose.
Market Dynamics
- Radioligand therapy label expansion, including Pluvicto's March 2025 broadening into an earlier prostate cancer setting
- Disclosed therapy revenue compounding fast from a small base: Pluvicto added roughly $600 million of revenue in FY2025 alone
- PSMA-targeted imaging demand pulling through to therapy selection, which links the diagnostic and therapeutic halves commercially
- Pipeline depth: 102 lutetium-177 studies registered on ClinicalTrials.gov as of October 2026
- New entrants scaling commercially - Telix group revenue reached US$803.8 million in FY2025, up 56%
Market Segmentation
By Type
- Diagnostic radiopharmaceuticals (SPECT)
- Diagnostic radiopharmaceuticals (PET)
- Therapeutic radiopharmaceuticals (beta emitters)
- Therapeutic radiopharmaceuticals (alpha emitters)
- Generators and cold kits
By End User
- Hospital nuclear medicine departments
- Independent imaging centres
- Radiopharmacies
- Academic and research centres
By Application
- Oncology
- Cardiology
- Neurology
- Endocrinology
- Bone and joint imaging
Competitive Landscape
Novartis
Switzerland
Reported Pluvicto net sales of USD 1,994 million (+43% in USD) and Lutathera net sales of USD 816 million (+13%) for FY2025, the two largest publicly disclosed radioligand therapy products. Together they are roughly 63% of all radiopharmaceutical product revenue we could find disclosed anywhere. Share of the total market is not disclosed and cannot be computed, because the largest commodity suppliers are private.
Lantheus Holdings
United States
Reported FY2025 group revenue of $1.54 billion and Pylarify revenue of $989.1 million, down 6.5%, with Q4 Pylarify down 9.7%. Guided FY2026 group revenue down to $1.40-1.45 billion. The clearest public evidence that the diagnostic half of this market is not growing.
Telix Pharmaceuticals
Australia
Reported FY2025 group revenue of US$803.8 million, up 56% from US$502.5 million, including a US$238.4 million distribution segment of which US$170.1 million was third-party product sales and service fees. Guided FY2026 to US$950-970 million. No market share is disclosed.
Curium Pharma
France
A principal supplier of generators, cold kits and SPECT agents. Privately held and publishes no product revenue, which is one reason no vendor share table in this category can be verified from public sources.
Cardinal Health Nuclear and Precision Health Solutions
United States
Operates a large US nuclear pharmacy network compounding and delivering unit doses. Revenue is not disclosed at product level within Cardinal Health's segment reporting, so its contribution to published market sizes cannot be isolated.
Bayer
Germany
Markets Xofigo (radium-223), the first approved alpha-emitting therapeutic radiopharmaceutical. Bayer does not break out Xofigo net sales in its public reporting, so the product sits inside published market sizes without a disclosed figure.
Regulatory Landscape
Research Methodology
Primary research
- No primary interviews were conducted for this edition. This report is a synthesis of company disclosures, public registers and published third-party estimates, and is labelled as such rather than implying fieldwork that did not occur.
Secondary research
- Novartis full-year 2025 results media release (2026): Pluvicto USD 1,994m, Lutathera USD 816m, group net sales USD 54,532m
- Lantheus Holdings Fourth Quarter and Full Year 2025 Financial Results, 26 February 2026: group revenue $1.54bn, Pylarify $989.1m (-6.5%), FY2026 guidance $1.40-1.45bn
- Telix Pharmaceuticals FY2025 Results, February 2026: group revenue US$803.8m, RLS segment US$238.4m including US$170.1m third-party product sales and service fees
- ClinicalTrials.gov API v2 interventional search for 'lutetium Lu 177': 102 registered studies, retrieved 16 October 2026
- Published market estimates from Precedence Research (2025), BCC Research, Towards Healthcare (2025), IMARC Group (2025), Market Research Future (2025), Roots Analysis (2025) and PS Market Research (2024)
- AJMC, 'Will the Coming Radiopharmaceutical Wave Reach More Patients With Cancer?', 10 April 2025, on Pluvicto's March 2025 label expansion
Validation: The headline figure is Precedence Research's published 2025 estimate of $7.51 billion advanced one year at Precedence's own published 7.53% CAGR to give a 2026 base of $8.08 billion; the intermediate years are interpolation on that single rate, not separately observed estimates. No methodology behind any published estimate was inspected. The grounding check is arithmetic, not an estimate: summing FY2025 disclosed product revenue for Pluvicto ($1,994m), Lutathera ($816m), Pylarify ($989.1m) and Telix's group revenue excluding its $170.1m of third-party distribution ($633.7m) gives $4.43 billion. That is 76% of IMARC's $5.8 billion market size, 59% of Precedence's $7.51 billion and 43% of BCC Research's $10.3 billion. Because the residual must cover all Tc-99m generator and FDG supply worldwide plus the private incumbents Curium and Cardinal Health Nuclear, the test rules out the bottom of the published range. It establishes a floor; it does not establish the correct market size, and is not offered as one.
Strategic Takeaways
Before using any radiopharmaceutical forecast, establish whether it is therapy-weighted or generator-weighted - that single assumption moves the growth rate by 3.35x
$4.43 billion was actually reported across four products in FY2025, and it already accounts for 76% of the lowest published estimate
the largest disclosed tracer fell 6.5% in 2025 and its owner guided 2026 lower
Treat any vendor share percentage for this market as unsourced, because the two largest commodity suppliers are private and disclose nothing
The therapy constraint is licensed delivering sites under 10 CFR Part 35, not demand, so model site capacity rather than incidence
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- PharmaceuticalsPsychedelic Therapeutics Market$3.6B · 15.4% CAGR
- PharmaceuticalsBiologics CDMO Market$20.9B · 11% CAGR
- PharmaceuticalsGlobal Drug Discovery AI Market$3.0B · 17.5% CAGR
- PharmaceuticalsGlobal Antibody Drug Conjugates Industry Size, Competitive Landscape and Regional Analysis$2.7B · 33.1% CAGR
- PharmaceuticalsGlobal Biosimilars Market$26.5B · 14.5% CAGR
- PharmaceuticalsGlobal RNA Therapeutics Market$2.0B · 12.7% CAGR